Elliptic Laboratories AS Cash Flow-to-Debt Ratio
Elliptic Laboratories AS cash flow-to-debt ratio. Elliptic Laboratories AS (ELABS) has a Cash Flow-to-Debt Ratio of -0.53x as of March 2026, meaning its operating cash flow of Nkr-17.60 Million could theoretically repay -1% of its total liabilities (Nkr33.36 Million) in one year. Check Elliptic Laboratories AS earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Elliptic Laboratories AS (2017–2025)
Cash flow-to-debt ratio of Elliptic Laboratories AS from 2017 to 2025. Historical debt coverage capacity for Elliptic Laboratories AS across 9 annual periods. Check Elliptic Laboratories AS cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Elliptic Laboratories AS Cash Flow-to-Debt Ratio by Year (2017–2025)
Elliptic Laboratories AS cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Elliptic Laboratories AS. For the full cash flow conversion analysis, see ELABS operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (NOK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.19x | Nkr5.99 Million | Nkr31.87 Million | ▲ +163.3% |
| 2024 | -0.30x | Nkr-10.61 Million | Nkr35.69 Million | ▲ +72.0% |
| 2023 | -1.06x | Nkr-45.51 Million | Nkr42.80 Million | ▼ -97.5% |
| 2022 | -0.54x | Nkr-12.76 Million | Nkr23.70 Million | ▼ -42.2% |
| 2021 | -0.38x | Nkr-10.82 Million | Nkr28.59 Million | ▼ -73.6% |
| 2020 | -0.22x | Nkr-6.68 Million | Nkr30.62 Million | ▼ -60.8% |
| 2019 | -0.14x | Nkr-8.05 Million | Nkr59.34 Million | ▲ +78.8% |
| 2018 | -0.64x | Nkr-35.16 Million | Nkr54.84 Million | ▲ +56.1% |
| 2017 | -1.46x | Nkr-38.87 Million | Nkr26.59 Million | — |